Aldosterone Promotes Thrombosis Formation After Arterial Injury in Mice
2005; Lippincott Williams & Wilkins; Volume: 26; Issue: 1 Linguagem: Inglês
10.1161/01.atv.0000195782.07637.44
ISSN1524-4636
AutoresPeter F. Bodary, C. Sambaziotis, Kevin J. Wickenheiser, Sanjay Rajagopalan, Bertram Pitt, Daniel T. Eitzman,
Tópico(s)Cardiovascular, Neuropeptides, and Oxidative Stress Research
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 26, No. 1Aldosterone Promotes Thrombosis Formation After Arterial Injury in Mice Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBAldosterone Promotes Thrombosis Formation After Arterial Injury in Mice P.F. Bodary, C. Sambaziotis, K.J. Wickenheiser, S. Rajagopalan, B. Pitt and D.T. Eitzman P.F. BodaryP.F. Bodary University of Michigan Medical Center Ann Arbor, Mich , C. SambaziotisC. Sambaziotis University of Michigan Medical Center Ann Arbor, Mich , K.J. WickenheiserK.J. Wickenheiser University of Michigan Medical Center Ann Arbor, Mich , S. RajagopalanS. Rajagopalan University of Michigan Medical Center Ann Arbor, Mich , B. PittB. Pitt University of Michigan Medical Center Ann Arbor, Mich and D.T. EitzmanD.T. Eitzman University of Michigan Medical Center Ann Arbor, Mich Originally published1 Jan 2006https://doi.org/10.1161/01.ATV.0000195782.07637.44Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:233To the Editor:The renin/angiotensin/aldosterone system (RAAS) has been broadly implicated in the pathogenesis of cardiovascular disease.1 Angiotensin converting enzyme (ACE) inhibitors have been shown to be beneficial in reducing cardiovascular events.2 The specific role of aldosterone in promoting ischemic cardiovascular disease is unclear. Recent evidence suggests that subjects with primary aldosteronism are at increased risk of cardiovascular events compared with subjects with essential hypertension,3 suggesting a potential direct role of aldosterone in mediating ischemic events. Human studies have demonstrated that pharmacological blockade of aldosterone with spironolactone in congestive heart failure patients leads to reduced cardiovascular mortality, even in the presence of ACE inhibition.4 Because many cardiovascular events are attributable to thrombosis in the setting of atherosclerosis, we used an animal model to directly determine the effect of elevated aldosterone on atherosclerosis as well as arterial thrombus formation after carotid artery injury.Previous studies in apolipoprotein E–deficient mice examining the role of exogenous aldosterone in atherosclerosis have produced conflicting results with either increased5 or neutral effects.6 To further examine this issue, we used the LDL receptor–deficient mouse model of atherosclerosis on a Western chow diet. Mice were divided into two groups to receive either placebo or 90-day slow-release aldosterone pellet (0.55 μg/d; Innovative Research of America). Seven days after pellet implantation, urinary aldosterone levels were elevated &2.7-fold (Aldo: 8.3±0.8 ng/mg creatinine; Placebo: 3.0±0.28 ng/mg creatinine; P=0.003). At the end of the protocol, mice were perfusion fixed and the aorta and major branches were dissected and removed as previously described.7 Atherosclerosis was quantitated after staining with oil red O. No difference in the total lesion area between aldosterone-treated and placebo pellet mice was observed (Aldo: 4.8±0.88 mm2 [n=5]; Placebo: 3.5±0.49 mm2 [n=4]; P=0.26). Similarly, cross-sectional analyses did not reveal differences in the aortic intima to media (IM) ratio (Aldo: 0.26±0.10 [n=4]; Placebo: 0.21±0.03 [n=5]; P=0.60). We also examined whether effects of aldosterone on atherosclerosis might be revealed in the presence of a high sodium diet (&3% NaCl) rather than Western chow. However, 3 weeks of treatment with aldosterone had no effect on atherosclerosis in the 20-week-old LDL receptor–deficient mice as determined by the aortic IM ratio (Aldo: 0.10±0.027 [n=4]; Placebo: 0.06±0.016 [n=4]; P=0.22). Although our results are limited by modest statistical power, we did not observe a major increase in atherosclerotic lesions at this dose of aldosterone.To investigate a possible effect of aldosterone on thrombosis, atherosclerotic mice on the Western chow diet were subjected to carotid photochemical injury before euthanization as previously described.7 Ninety days of aldosterone treatment resulted in a marked shortening of the time to occlusive thrombus formation in these hyperlipidemic atherosclerotic mice (aldosterone: 13±2.0 minutes, n=5; Placebo: 23±2.3 minutes, n=4; P=0.01). This is the first experimental evidence of aldosterone treatment resulting in enhanced thrombus formation following arterial injury.To further examine the effect of aldosterone toward enhanced thrombosis, we determined whether aldosterone treatment in the absence of hyperlipidemia and atherosclerosis produced a similar prothrombotic effect. For these studies we measured the time to occlusive thrombus formation in wild-type mice (C57BL6/J) provided a placebo or aldosterone pellet using the same dosing regimen, but for only 20 days. As shown in the Figure, we observed that this aldosterone treatment also resulted in enhanced thrombus formation after photochemical injury. Furthermore, this effect was prevented by coinfusion of the aldosterone antagonist, spironolactone (&1 mg/d per mouse; Figure). These data provide strong evidence of a direct aldosterone effect on thrombosis and demonstrate that this effect can be blocked with spironolactone. Download figureDownload PowerPointSix- to ten-week-old male mice were each provided two implanted pellets providing either aldosterone/placebo or spironolactone/placebo. The 3 groups examined received either two placebo pellets (placebo; n=10), one aldosterone and one placebo pellet (aldo; n=11), or one of each (Aldo/Spiro; n=11). The percentage of mice with patent arteries in each group are plotted in a Kaplan–Meier graph as a function of time after initiation of photochemical injury. A cox proportional hazard model was used to compare groups as described previously.8 *Significant difference compared with placebo; +significant difference compared with aldosterone (Aldo) group.These findings indicate that aldosterone blockade may be beneficial in subjects at risk for arterial thrombotic events. Additional studies are necessary to delineate the mechanism of this aldosterone-mediated prothrombotic effect.1 Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med. 2003; 163: 1155–1164.CrossrefMedlineGoogle Scholar2 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145–153.CrossrefMedlineGoogle Scholar3 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243–1248.CrossrefMedlineGoogle Scholar4 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709–717.CrossrefMedlineGoogle Scholar5 Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004; 109: 2213–2220.LinkGoogle Scholar6 Cassis LA, Helton MJ, Howatt DA, King VL, Daugherty A. Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Br J Pharmacol. 2005; 144: 443–448.CrossrefMedlineGoogle Scholar7 Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation. 2001; 103: 3044–3046.CrossrefMedlineGoogle Scholar8 Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005; 105: 192–198.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByBuffolo F, Tetti M, Mulatero P and Monticone S (2022) Aldosterone as a Mediator of Cardiovascular Damage, Hypertension, 79:9, (1899-1911), Online publication date: 1-Sep-2022.Gromotowicz‐Poplawska A, Flaumenhaft R, Gholami S, Merrill‐Skoloff G, Chabielska E, Williams G and Romero J (2021) Enhanced Thrombotic Responses Are Associated With Striatin Deficiency and Aldosterone, Journal of the American Heart Association, 10:22, Online publication date: 16-Nov-2021. Gadasheva Y, Nolze A and Grossmann C (2021) Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging, Frontiers in Molecular Biosciences, 10.3389/fmolb.2021.667990, 8 Gromotowicz-Poplawska A, Szoka P, Zakrzeska A, Kolodziejczyk P, Marcinczyk N, Szemraj J, Tutka P and Chabielska E (2021) Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model, Cells, 10.3390/cells10020471, 10:2, (471) Barrera-Chimal J and Jaisser F (2019) Vascular mineralocorticoid receptor activation and disease, Experimental Eye Research, 10.1016/j.exer.2019.107796, 188, (107796), Online publication date: 1-Nov-2019. Chen B, Wang P, Brem A, Dworkin L, Liu Z and Gong R (2019) Mineralocorticoid receptor: A hidden culprit for hemodialysis vascular access dysfunction, EBioMedicine, 10.1016/j.ebiom.2018.11.054, 39, (621-627), Online publication date: 1-Jan-2019. Parker B, Wertz S, Pollard C, Desimine V, Maning J, McCrink K and Lymperopoulos A (2018) Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease, International Journal of Molecular Sciences, 10.3390/ijms19123764, 19:12, (3764) Allingham M, Tserentsoodol N, Saloupis P, Mettu P and Cousins S (2018) Aldosterone Exposure Causes Increased Retinal Edema and Severe Retinopathy Following Laser-Induced Retinal Vein Occlusion in Mice, Investigative Opthalmology & Visual Science, 10.1167/iovs.17-23073, 59:8, (3355), Online publication date: 9-Jul-2018. Marzolla V, Armani A, Mammi C, Moss M, Pagliarini V, Pontecorvo L, Antelmi A, Fabbri A, Rosano G, Jaffe I and Caprio M (2017) Essential role of ICAM-1 in aldosterone-induced atherosclerosis, International Journal of Cardiology, 10.1016/j.ijcard.2017.01.013, 232, (233-242), Online publication date: 1-Apr-2017. Gromotowicz-Poplawska A, Szoka P, Kolodziejczyk P, Kramkowski K, Wojewodzka-Zelezniakowicz M and Chabielska E (2016) New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?, Experimental Biology and Medicine, 10.1177/1535370216660211, 241:17, (1888-1899), Online publication date: 1-Nov-2016. Moss M and Jaffe I (2015) Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis, Frontiers in Endocrinology, 10.3389/fendo.2015.00153, 6 Lother A, Moser M, Bode C, Feldman R and Hein L (2015) Mineralocorticoids in the Heart and Vasculature: New Insights for Old Hormones, Annual Review of Pharmacology and Toxicology, 10.1146/annurev-pharmtox-010814-124302, 55:1, (289-312), Online publication date: 6-Jan-2015. Young M and Rickard A Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals, Journal of Endocrinology, 10.1530/JOE-14-0471, 224:1, (R1-R13) Lagrange J, Li Z, Fassot C, Bourhim M, Louis H, Cat A, Parlakian A, Wahl D, Lacolley P, Jaisser F and Regnault V (2014) Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice, The FASEB Journal, 10.1096/fj.13-238188, 28:5, (2062-2072), Online publication date: 1-May-2014. Gromotowicz A, Szemraj J, Stankiewicz A, Zakrzeska A, Mantur M, Jaroszewicz E, Rogowski F and Chabielska E (2011) Study of the mechanisms of aldosterone prothrombotic effect in rats, Journal of the Renin-Angiotensin-Aldosterone System, 10.1177/1470320310397405, 12:4, (430-439), Online publication date: 1-Dec-2011. Lindschau C, Kirsch T, Klinge U, Kolkhof P, Peters I and Fiebeler A (2011) Dehydroepiandrosterone-Induced Phosphorylation and Translocation of FoxO1 Depend on the Mineralocorticoid Receptor, Hypertension, 58:3, (471-478), Online publication date: 1-Sep-2011. Taye A, Sawamura T and Morawietz H (2010) Aldosterone augments LOX-1-mediated low-density lipoprotein uptake in human umbilical artery endothelial cells, Pharmacological Reports, 10.1016/S1734-1140(10)70271-1, 62:2, (311-318), Online publication date: 1-Mar-2010. Fiebeler A, Muller D, Shagdarsuren E and Luft F (2007) Aldosterone, mineralocorticoid receptors, and vascular inflammation, Current Opinion in Internal Medicine, 10.1097/MNH.0b013e32801245bb, 6:3, (295-303), Online publication date: 1-Jun-2007. Calò L and Armanini D (2014) Aldosterone and thrombosis formation: Implications for ischemic and atherosclerotic heart disease, Journal of Endocrinological Investigation, 10.1007/BF03344170, 29:7, (675-676), Online publication date: 1-Jul-2006. January 2006Vol 26, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.0000195782.07637.44PMID: 16373624 Originally publishedJanuary 1, 2006 PDF download Advertisement
Referência(s)